NCT04538742: A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742
Breast Cancer Type: HER2+
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with prior treatment of immune checkpoint inhibitors, an antibody-drug (ADC) containing a topoisomerase I inhibitor, or tucatinib
https://ClinicalTrials.gov/show/NCT04538742

Comments are closed.

Up ↑